Clene (CLNN) Metrics: History & Chart

Clene Inc.(CLNN)

Biotechnology · Salt Lake City, UT

$3.90-0.01 (-0.26%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Salt Lake City, UT

78 employees

clene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Etherington

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-3.69%
30D Total Return	+1.56%
YTD Total Return	-33.39%
1Y Total Return	-62.80%
3Y Total Return	-64.04%
5Y Total Return	-97.22%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-33.39%
2025	+10.55%
2024	-10.46%
2023	-70.35%
2022	-75.61%
2021	-54.50%
2020

CAGR TTM	-62.62%
CAGR 3Y	-28.88%
CAGR 5Y	-51.16%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	5.09
PE Ratio Avg TTM	13.56
PE Ratio Avg 3Y	13.56
Current VS TTM Avg	-62.46%
Current VS 3Y Avg	-62.46%
Current VS 5Y Avg	-62.46%

All Metrics

CLNN Valuation Metrics

CLNN Stock Price Metrics

CLNN Dividend Metrics

CLNN Growth Rate Metrics

CLNN Discounted Cash Flow Metrics

CLNN Returns By Period

CLNN Yearly Returns

CLNN Average Annual Returns By Period (CAGR)

CLNN Revenue Metrics

CLNN PE Ratio Metrics

CLNN PS Ratio Metrics

CLNN PB Ratio Metrics

CLNN Price to Free Cash Flow Ratio Metrics

CLNN Debt to Equity Ratio Metrics

CLNN PEG Ratio Metrics

CLNN FCF Yield

CLNN Earnings Yield

CLNN EBITDA Yield

CLNN OCF Yield

CLNN EV/EBIT Ratio Metrics

CLNN EV/EBITDA Ratio Metrics

CLNN EV/Assets Ratio Metrics

CLNN EV/Sales Ratio Metrics

CLNN Current Ratio Metrics

CLNN Quick Ratio Metrics

CLNN ROIC Metrics

CLNN Return on Assets Metrics

CLNN Return on Equity Metrics

CLNN Net Profit Margin Metrics

CLNN Gross Profit Margin Metrics

CLNN Tax Rate Metrics

PS Ratio	245.77
PS Ratio Avg TTM	342.08
PS Ratio Avg 3Y	163.43
Current VS TTM Avg	-28.15%
Current VS 3Y Avg	+50.38%
Current VS 5Y Avg	+18.56%

PB Ratio	6.78
PB Ratio Avg TTM	3.17
PB Ratio Avg 3Y	20.95
Current VS TTM Avg	+113.81%
Current VS 3Y Avg	-67.64%
Current VS 5Y Avg	-73.47%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	(0.90)
Debt/Equity Ratio Avg TTM	(1.49)
Debt/Equity Ratio Avg 3Y	(1.29)
Current VS TTM Avg	+39.63%
Current VS 3Y Avg	+30.09%
Current VS 5Y Avg	-258.89%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	19.66%
Earnings Yield Avg TTM	7.53%
Earnings Yield Avg 3Y	7.53%
Current VS TTM Avg	+160.99%
Current VS 3Y Avg	+160.99%
Current VS 5Y Avg	+160.99%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	2.65
Ev/Assets Ratio Avg TTM	3.68
Ev/Assets Ratio Avg 3Y	2.07
Current VS TTM Avg	-28.09%
Current VS 3Y Avg	+28.21%
Current VS 5Y Avg	+12.04%

Ev/Sales Ratio	310.10
Ev/Sales Ratio Avg TTM	420.85
Ev/Sales Ratio Avg 3Y	199.99
Current VS TTM Avg	-26.32%
Current VS 3Y Avg	+55.06%
Current VS 5Y Avg	+29.60%

Current Ratio	3.07
Current Ratio Avg TTM	1.79
Current Ratio Avg 3Y	1.34
Current VS TTM Avg	+71.72%
Current VS 3Y Avg	+129.55%
Current VS 5Y Avg	+35.84%

Quick Ratio	3.07
Quick Ratio Avg TTM	1.78
Quick Ratio Avg 3Y	1.33
Current VS TTM Avg	+72.00%
Current VS 3Y Avg	+129.82%
Current VS 5Y Avg	+35.85%

ROIC	(109.13%)
ROIC Avg 3Y	(134.00%)
ROIC Avg 5Y	(125.36%)
Current VS 3Y Avg	+18.56%
Current VS 5Y Avg	+12.95%
Current VS 10Y Avg	+7.18%

ROA	(171.51%)
ROA Avg TTM	(43.87%)
ROA Avg 3Y	(30.70%)
Current VS TTM Avg	-290.93%
Current VS 3Y Avg	-458.67%
Current VS 5Y Avg	-692.29%

ROE	N/A
ROE Avg TTM	(427.48%)
ROE Avg 3Y	(170.94%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(20059.90%)
Net Profit Margin Avg TTM	(33365.70%)
Net Profit Margin Avg 3Y	(9209.68%)
Current VS TTM Avg	+39.88%
Current VS 3Y Avg	-117.81%
Current VS 5Y Avg	-127.75%

Gross Profit Margin	78.50%
Gross Pft Margin Avg TTM	(387.31%)
Gross Pft Margin Avg 3Y	76.40%
Current VS TTM Avg	+120.27%
Current VS 3Y Avg	+2.75%
Current VS 5Y Avg	-7.60%

Tax Rate	(5.11%)
Tax Rate Avg 3Y	7.24%
Tax Rate Avg 5Y	7.24%
Current VS 3Y Avg	-170.61%
Current VS 5Y Avg	-170.61%
Current VS 10Y Avg	-170.61%